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Background: A number of previous studies have suggested that overweight or obese patients with coronary artery
disease (CAD) may have lower morbidity and mortality than their leaner counterparts. Few studies have addressed
possible gender differences, and the results are conflicting. We examined the association between body mass index
(BMI) and risk of acute myocardial infarction (AMI), cardiovascular (CV) death and all-cause mortality in men and
women with suspected stable angina pectoris.
Method: The cohort included 4164 patients with suspected stable angina undergoing elective coronary angiography
between 2000 and 2004. Events were registered until the end of 2006. Hazard ratios (HR) (95% confidence intervals)
were estimated using Cox regression by comparing normal weight (18.5-24.9 kg/m2) with overweight (25–29.9 kg/m2)
and obese (≥30 kg/m2) patients. Underweight (<18.5 kg/m2) patients were excluded from the study.
Results: Of 4131 patients with complete data, 72% were males and 75% were diagnosed with significant CAD. The
mean (standard deviation (SD)) age in the total population was 62 (10) years. Mean (SD) BMI was 26.8 (3.9) kg/m2, 34%
was normal weight, 48% overweight and 19% obese. During follow up, a total of 337 (8.2%) experienced an AMI
and 302 (7.3%) patients died, of whom 165 (4.0%) died from cardiovascular causes. We observed a significant
interaction between BMI groups and gender with regards to risk of AMI (p = 0.011) and CV death (p = 0.031), but
not to risk of all-cause mortality; obese men had a multivariate adjusted increased risk of AMI (HR 1.80 (1.28, 2.52))
and CV death (HR 1.60 (1.00, 2.55)) compared to normal weight men. By contrast, overweight women had a decreased
risk of AMI (HR 0.56 (0.33, 0.98)) compared to normal weight women. The risk of all-cause mortality did not differ
between BMI categories.
Conclusion: Compared with normal weight subjects, obese men had an increased risk of AMI and CV death,
while overweight women had a decreased risk of AMI. These findings may potentially explain some of the result
variation in previous studies reporting on the obesity paradox.
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Cardiovascular disease (CVD) is the leading cause of death
globally: the majority dying from ischemic heart disease
[1]. Overweight and obesity, most commonly defined
according to body mass index (BMI), has been character-
ized as a major modifiable risk factor for cardiovascular
(CV) morbidity and mortality by the American Heart
Association and the American College of Cardiology [2].
As recently reviewed, some studies of patients with
coronary artery disease (CAD) suggest that being over-
weight or obese has beneficial effects in terms of reduced
risk of CV events and/or mortality; a phenomenon known
as the obesity paradox. However, there is no broad con-
sensus regarding the obesity paradox, as several studies
are unsupportive of this conclusion [3].
Moreover, despite the fact that both body fat percent-
age and distribution vary by gender [4], only a limited
number of studies among patients with CAD or suspected
CAD have examined the association between BMI and
risk of coronary events and mortality in men and women
separately, and the reported results are conflicting [5-9].
There is, however, a tendency towards a non-disadvanta-
geous [5,6,9] or even a beneficial [7] effect of overweight
and obesity among women, while obesity appears to
increase the risk of coronary events in men [5,6].
In the present study we examined the association
between BMI and risk of incident acute myocardial
infarction (AMI), CV death and all-cause mortality in
a large population of men and women with suspected
CAD. We hypothesized that overweight and/or obesity, as
compared to normal weight, was associated with an
increased risk of AMI, CV death and all-cause mortality
among men, but not among women.Methods
Study design and patient population
The patients recruited for the present investigation are
described in detail elsewhere [10]. In brief, 4164 patients
undergoing elective coronary angiography for suspected
stable angina pectoris were recruited from two university
hospitals in Western Norway from January 2000 to April
2004. Of these patients, 2573 (62.0%) were enrolled in the
Western Norway B Vitamin Intervention Trial (WENBIT)
which studied the prognostic impact of B-vitamin supple-
mentation upon incident CV events and mortality (clinical-
trials.gov Identifier: NCT00354081) [11]. Patients for whom
there was no BMI data (n = 3) were excluded from the
study, as were underweight patients (BMI < 18.5 kg/m2)
(n = 30).This left a total of 4131 subjects eligible for the
analyses.
The study protocol met the mandate of the Helsinki
Declaration, and was approved by the Western Norway
Regional Committee for Medical and Health ResearchEthics and the Norwegian Data Inspectorate. Written in-
formed consent was obtained from all participants.
Baseline data and biochemical analyses
Height, weight and blood pressure were measured at
baseline by trained study personnel. BMI was calculated
by dividing weight by height squared (kg/m2). Each
patient provided information about medical history,
risk factors and medications through a self-administered
questionnaire, and all information was subsequently
validated against medical records. Diabetes mellitus
included type 1 and 2. Current smokers included those
with self-reported current smoking, those who had quit
smoking within <1 month and those with plasma cotin-
ine >85 ng/mL [12]. Patients, who reported to have quit
smoking > 1 month prior to inclusion and had plasma
cotinine levels ≤85 ng/mL, were categorized as ex-smokers.
Pulmonary disease included chronic obstructive lung
disease, other chronic lung diseases and pulmonal hyper-
tension. Cancer included active cancer with or without
metastases. Family history of early coronary heart disease
(CHD) encompassed those reporting to have at least one
1st degree relative suffering from CHD before the age of
55 for men and 65 for women. Left ventricular ejection
fraction (LVEF) was determined by ventriculography or
echocardiography. The extent of CAD at angiography was
scored as 0–3 as has previously been described [11]. Base-
line coronary revascularisation procedures, after baseline
angiography, included percutaneous coronary intervention
(PCI) and coronary artery bypass graft surgery (CABG).
Blood samples were collected by study personnel prior
to angiography and stored at −80˚C until analysis. Serum
apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB)
and lipoprotein (a) (Lp(a)) were analysed on the Hitachi
917 system (Roche Diagnostics, GmbH, Mannheim,
Germany). Serum C-reactive protein (CRP) was measured
using a latex, high sensitive assay (Behring Diagnostics,
Marburg, Germany). Plasma cotinine was measured by
liquid chromatography/tandem mass spectrometry [13].
Low density lipoprotein (LDL) cholesterol was calculated
using the Friedewald formula [14] and estimated glomeru-
lar filtration rate (eGFR) was estimated using the Chronic
Kidney Disease Epidemiology Collaboration formula [15].
Follow-up and end points
The study participants were followed from angiography
until they experienced one of the primary endpoints; AMI
(fatal or non-fatal), death or till December 31st 2006.
Information on clinical events was collected from The
Western Norway Cardiovascular Registry and from the
Cause of Death Registry at Statistics Norway as previously
described [11]. An event was classified as fatal if death
occurred within 28 days after onset. AMI was classified
according to the diagnostic criteria of the revised AMI
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classified according to diagnostic criteria published in
2001 [17]. Procedure-related non-fatal AMI occurring
within 24 h of coronary angiography, PCI or CABG
were not included in the end-point. CV death included
causes of death coded I00-I99 or R96, according to the
International Statistical Evaluation of Disease, Tenth
Revision system. An endpoints committee adjudicated
all events.
Statistical analysis
Continuous variables are presented as means (standard
deviation (SD)). Categorical variables are reported as counts
(percentage). Non-normally distributed variables (diastolic
blood pressure, serum creatinine, CRP, plasma glucose,
serum triglycerides and Lp(a)) were log transformed.
BMI groups were created using established BMI cut-offs;
Normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI
25–29.9 kg/m2) and obesity (BMI ≥30 kg/m2). Under-
weight patients (n = 30) were eliminated due to the possi-
bility of reverse causation. Between group differences were
tested by one-way analysis of variance (ANOVA) or inde-
pendent samples t-test for continuous variables, and by
chi square test for categorical variables. Post hoc tests
were applied for multiple comparisons where appropriate.
The relationships between baseline BMI and subsequent
risk of AMI, CV death and all-cause mortality were evalu-
ated across BMI groups. Hazard ratios (HR) and 95%
confidence intervals (CI) of endpoints associated with
BMI categories were estimated with Cox proportional
hazard models using the BMI normal weight category
as reference. The time, in days, from angiography until
endpoint (AMI, CV death and all-cause mortality) or
end of study (December 31st 2006) was used as time scale.
Proportionality assumptions were tested by visual examin-
ation of log minus log plots and calculating Schoenfeld
residuals. Covariates in the multivariate adjusted models
were selected based on clinical relevance and the change-
in-estimate method [18], with a limit for inclusion of
10% change in the risk ratio. The final multivariate
model included gender, age (continuous), LVEF (%),
current smoking (yes/no), angiotensin converting enzyme
(ACE) -inhibitors (yes/no), loop diuretics (yes/no) and
pulmonary disease (yes/no). Further adjustment of the
multivariate Cox model did not alter the results in the
total population or in gender stratified analyses; systolic
and diastolic blood pressure (mmHg), diabetes mellitus
(yes/no), previous AMI (yes/no), extent of significant CAD
(0–3), serum creatinine levels (μmol/L), CRP (mg/L), total
cholesterol (mmol/L), vitamin B6 (yes/no) or folate/B12
(yes/no) intervention status (data not shown).
Effect modifications by gender were investigated by
including the product of gender and BMI categories as an
interaction term in the multivariate adjusted Cox model.All tests were 2-sided, and a p-value <0.05 was consid-
ered significant. Statistical analyses were performed with
SPSS 17 (SPSS Inc, Chicago, IL) and R 2.14.2 (The R-
Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics
The cohort consisted of 4131 patients (72% males), and
the mean (SD) age in the total population was 62 (10)
years. Baseline characteristics across BMI groups are
presented in Table 1. The mean (SD) BMI was 26.8 (3.9)
kg/m2, and 34% of the patients had a BMI within the
normal weight range, 48% were overweight and 19%
were obese.
Compared to the overweight and obese groups, the
normal weight group was characterised by older age and
a higher proportion of current smokers and subjects
with a history of peripheral arterial disease. Mean blood
pressure was lower in this group, as was the prevalence
of diabetes. The extent of CAD at baseline did, however,
not differ between the BMI categories. Compared to
normal weight patients, overweight and obese patients
were more often discharged with aspirin, statins and
beta-blockers, while ACE inhibitors and loop diuretics
were more often prescribed to obese patients.
The levels of eGFR, serum CRP, plasma glucose, HbA1c,
Hb, serum ApoB, triglyceride and Lp(a) increased across
incremental BMI groups, while serum ApoA1 and HDL
cholesterol levels declined.
Baseline characteristics according to gender
Among men, 32% were normal weight, 51% overweight
and 17% obese, whereas the respective proportions were
38%, 40% and 22% among women. Mean (SD) BMI was
26.8 (3.7) kg/m2 among men and 26.8 (4.7) kg/m2 among
women.
Baseline characteristics according to gender and BMI
groups are presented in Table 2. Compared to women,
men were generally younger, and there was an inverse
relationship between age and BMI among men. Men had
worse CV risk profile and more severe CAD, at baseline,
than women. Correspondingly, men, compared to women,
did more often undergo revascularisation procedures
following baseline angiography and were more often
discharged with medication.
Follow-up and end-points
During the follow-up period (mean (SD) 4.8 (1.4) years),
337 (8.2%) patients experienced an AMI, of which 101
(30%) were fatal. A total of 302 (7.3%) patients died, of
whom 165 (55%) died from cardiovascular causes.
There were statistically significant multivariate adjusted
interactions between gender and BMI categories with
regards to risk of incident AMI (p-int = 0.011) and
Table 1 Baseline characteristics and laboratory findings according to BMI groupsa
Total n = 4131 Normal weight n = 1395 Overweight n = 1970 Obese n = 766 p-valueb
Demographic characteristics
Male sex, n (%) 2989 (72.4) 959 (68.7) 1517 (77.0) 513 (67.0) <0.001
Age (years)c 62 (10) 63 (11) 61 (10) 60 (10) <0.001
Clinical parameters
Systolic blood pressure (mmHg) 141 (20.7) 139 (21.0) 142 (20.6) 143 (20.3) <0.001
Diastolic blood pressure (mmHg) 81.3 (10.4) 79.3 (10.3) 82.0 (10.1) 83.3 (10.7) <0.001
Left ventricular ejection fraction (%) 64.0 (11.3) 63.7 (11.9) 64.4 (10.7) 63.6 (11.8) 0.08
Cardiovascular risk factors, n (%)
Diabetesd 496 (12.0) 123 (8.8) 209 (10.6) 164 (21.4) <0.001
Current smokere 1061 (25.7) 417 (29.9) 469 (23.9) 175 (22.9) <0.001
Ex smokerf 1933 (46.9) 571 (40.6) 975 (49.6) 387 (50.7) <0.001
Family history of coronary heart diseaseg 1253 (31.1) 417 (30.8) 573 (29.7) 263 (35.1) 0.02
Cardiovascular history, n (%)
Previous acute myocardial infarction 1670 (40.4) 564 (40.4) 784 (39.8) 322 (42.0) 0.56
Previous cerebrovascular disease 286 (6.9) 100 (7.2) 128 (6.5) 58 (7.6) 0.55
Previous peripheral vascular arterial disease 371 (9.0) 153 (11.0) 148 (7.5) 70 (9.1) <0.01
Previous percutaneous coronary intervention 794 (19.2) 250 (17.9) 396 (20.1) 148 (19.3) 0.29
Previous coronary artery bypass graft surgery 477 (11.5) 150 (10.8) 238 (12.1) 89 (11.6) 0.49
Extent of coronary artery disease at baseline as assessed by coronary angiography, n (%)
No significant coronary artery disease 1030 (24.9) 367 (26.3) 467 (23.7) 196 (25.6) 0.21
1-vessel disease 958 (23.2) 306 (21.9) 482 (24.5) 170 (22.2) 0.18
2-vessel disease 923 (22.3) 308 (22.1) 440 (22.3) 175 (22.8) 0.92
3-vesseldisease 1220 (29.5) 414 (29.7) 581 (29.5) 225 (29.4) 0.99
Comorbidity at baseline, n (%)
Pulmonary disease 367 (8.9) 139 (10.0) 140 (7.1) 88 (11.5) <0.001
Cancer 4 (0.1) 2 (0.1) 1 (0.1) 1 (0.1) 0.66
Medication following baseline coronary angiography, n (%)
Acetylsalisylic acid 3376 (81.7) 1114 (79.9) 1638 (83.1) 624 (81.5) 0.05
Statins 3310 (80.1) 1064 (76.3) 1626 (82.5) 620 (80.9) <0.001
β-blockers 2994 (72.5) 970 (69.5) 1456 (73.9) 568 (74.2) 0.01
ACE inhibitors 858 (20.8) 243 (17.4) 403 (20.5) 212 (27.7) <0.001
Loop diuretics 447 (10.8) 127 (9.1) 182 (9.2) 138 (18.0) <0.001
Coronary revascularization following baseline coronary angiography, n (%)
Percutaneous coronary intervention 1348 (32.6) 432 (31.0) 663 (33.7) 253 (33.0) 0.26
Coronary artery bypass graft surgery 892 (21.6) 302 (21.6) 438 (22.2) 152 (19.8) 0.39
Biochemical markers
Creatinine (μmol/L) 92.6 (31.1) 92.5 (33.4) 93.0 (32.0) 91.8 (23.4) 0.34
eGFR (mL/min) 87.8 (17.3) 86.2 (17.7) 88.5 (16.6) 88.9 (17.8) <0.001
CRP (mg/L) 3.69 (7.17) 3.34 (7.93) 3.59 (6.67) 4.60 (6.85) <0.001
Glucose (mmol/L) 6.35 (2.40) 5.93 (2.24) 6.32 (2.28) 7.20 (2.79) <0.001
HbA1c (mmol/L) 6.22 (1.38) 6.12 (1.28) 6.18 (1.41) 6.51 (1.45) <0.001
Hemoglobin (g/dL) 14.2 (1.24) 13.9 (1.24) 14.4 (1.18) 14.4 (1.29) <0.001
ApoA1 (g/L) 1.32 (0.27) 1.37 (0.29) 1.30 (0.25) 1.27 (0.26) <0.001
ApoB (g/L) 0.90 (0.25) 0.87 (0.24) 0.91 (0.24) 0.93 (0.26) <0.001
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Table 1 Baseline characteristics and laboratory findings according to BMI groupsa (Continued)
Total cholesterol (mmol/L) 5.07 (1.17) 5.02 (1.14) 5.08 (1.18) 5.10 (1.19) 0.13
LDL cholesterol (mmol/L) 3.09 (1.03) 3.05 (1.02) 3.12 (1.00) 3.11 (1.10) 0.11
HDL cholesterol (mmol/L) 1.29 (0.38) 1.42 (0.43) 1.25 (0.34) 1.17 (0.32) <0.001
Triglycerides (mmol/L) 1.78 (1.22) 1.43 (0.90) 1.86 (1.28) 2.22 (1.39) <0.001
Lp(a) (mmol/L) 0.42 (0.39) 0.41 (0.39) 0.43 (0.39) 0.42 (0.39) 0.03
WENBIT intervention trial, n (%) 2560 (62.0) 797 (57.1) 1283 (65.1) 480 (62.7) <0.001
B6, n (% of WENBIT participants) 1275 (49.8) 394 (49.4) 657 (51.2) 224 (46.7) <0.01
Folate/B12, n (% of WENBIT participants) 1282 (50.1) 409 (51.3) 649 (50.6) 224 (46.7) 0.04
ACE, angiotensin converting enzyme; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, body mass index; CRP, c-reactive protein; eGFR, esitimated glomerular
filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; Lp(a), lipoprotein (a).
aNormal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2).
bBased on between group differences calculated by one-way analysis of variance (ANOVA) for continuous variables and Chi squared test for categorical variables.
cMean (SD).
dIncludes DM type 1 and 2.
eSmokers included self-reported current smoking, those who quit smoking within <1 month and patients with plasma cotinine >85 ng/mL.
fPatients reported to have quit smoking > 1 month prior to inclusion.
gIncluded those reporting to have at least one 1st degree relative suffering from CAD before the age of 55 for men and 65 for women.
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(p-int = 0.427).
A total of 115 (8.2%) normal weight patients, 127 (6.4%)
overweight patients and 60 (7.8%) obese patients died.
The risk of all-cause mortality did not differ significantly
between BMI categories in any analyses; compared to the
normal weight group, the multivariate adjusted HR (95%
CI) was 0.95 (0.74, 1.23) in the overweight group and 1.16
(0.84, 1.60) in the obese group.
Analyses were repeated in subgroups of patients with
significant CAD or without diabetes only, and the results
were not significantly different from those reported (data
not shown).
Gender stratified analyses
A total of 267 (8.9%) men and 70 (6.1%) women suffered
an AMI. Further, 241 (8.1%) men and 61 (5.3%) women
died, whereof 132 (55%) male deaths and 33 (54%)
female deaths were characterised as CV deaths.
Obese men had a significantly higher multivariate
adjusted risk of both incident AMI; HR 1.80 (1.28, 2.52),
and CV death; HR 1.60 (1.00, 2.55), compared to normal
weight men (Table 3).
Overweight women had a significantly lower multivari-
ate adjusted risk of AMI; HR 0.56 (0.33, 0.98), compared
to normal weight women (Table 4). By contrast, the multi-
variate adjusted HR for AMI between normal weight
women and obese women did not differ significantly.
Discussion
Principal findings
In this large longitudinal prospective cohort study of
more than 4000 patients with suspected stable angina
pectoris, we demonstrate that obese male patients had a
1.8 fold and 1.6 fold increased risk of incident AMI and
CV death compared to normal weight men. By contrast,compared to normal weight women, obese women had
similar risk of AMI and CV death, while overweight
women had nearly half the risk of incident AMI. The
risk of all-cause mortality associated with BMI was
similar among men and women, and did not differ sig-
nificantly across BMI categories.
BMI and risk of AMI, CV death and all-cause mortality in
men and women
Strong associations between overweight/obesity and risk
of CVD and death have been demonstrated in the general
population [19,20]. By contrast, several studies of patients
with CAD have demonstrated that overweight and/or
obese patients may have a better morbidity and mortality
prognosis than their leaner counterparts; although as one
recent review points out, this observation is not supported
by all [3].
Only a few studies of patients with CAD have exam-
ined the association between BMI and risk of CV events
and mortality in men and women separately. Our finding
of an increased risk of cardiovascular events among obese
men are in accordance with the results from a previous
US study of patients with stable CVD, whereof 85%
had CHD, as well as with a multi-ethnic sample study
of patients with established CAD [5,6]. However, while
these studies did not observe any significant associations
between BMI and risk of major adverse coronary events
in women, we report a nearly halved adjusted risk of AMI
among overweight women as compared to their normal
weight counterparts.
In the present study, there was no interaction between
BMI and gender with regards to all-cause mortality.
Moreover, the risk of death did not differ between BMI
groups. These findings are in accordance with a previous
study conducted among European patients with CAD
[21]. To the best of our knowledge only two studies,
Table 2 Baseline characteristics and laboratory findings according to gender and BMI groupsa
Men Women
Total Normal weight Overweight Obese Total Normal weight Overweight Obese
n = 2989 n = 959 n = 1517 n = 513 p-valueb n = 1142 n = 436 n = 453 n = 253 p-valuec p-valued
Demographic characteristics
Age (years)e 61 (10) 63 (11) 61 (10) 59 (10) <0.001 63 (10) 63 (19) 64 (11) 63 (10) 0.52 <0.001
Clinical parameters
Systolic blood pressure (mmHg) 141 (20.4) 140 (20.5) 141 (20.3) 143 (20.4) 0.03 141 (21.6) 138 (22.1) 143 (21.6) 144 (20.2) <0.01 0.94
Diastolic blood pressure (mmHg) 81.8 (10.4) 79.6 (10.1) 82.2 (10.0) 84.3 (11.1) <0.001 80.0 (10.3) 78.4 (10.8) 80.9 (10.1) 81.0 (9.60) <0.001 <0.001
Left ventricular ejection fraction (%) 63.1 (11.8) 62.6 (12.4) 63.7 (11.1) 62.1 (12.4) <0.01 66.5 (9.81) 65.9 (10.3) 66.9 (9.21) 66.8 (9.93) 0.30 <0.001
Cardiovascular risk factors, n (%)
Diabetesf 361 (12.1) 97 (10.1) 158 (10.4) 106 (20.7) <0.001 135 (11.8) 26 (6.0) 51 (11.3) 58 (22.9) <0.001 0.82
Current smokerg 803 (26.9) 305 (31.8) 375 (24.8) 123 (24.0) <0.001 258 (22.7) 112 (25.7) 94 (20.8) 52 (22.7) 0.16 <0.01
Ex smokerh 1595 (53.4) 448 (46.7) 842 (55.6) 305 (59.6) <0.001 338 (29.7) 123 (28.2) 133 (29.5) 82 (32.7) 0.47 <0.001
Family history of coronary heart diseasei 844 (29.0) 258 (27.8) 417 (28.1) 169 (33.9) 0.03 409 (36.4) 159 (37.3) 156 (34.9) 94 (37.6) 0.69 <0.001
Cardiovascular history, n (%)
Previous acute myocardial infarction 1346 (45.9) 429 (44.7) 668 (44.0) 249 (48.5) 0.20 324 (28.4) 135 (31.0) 116 (25.6) 73 (28.9) 0.21 <0.001
Previous cerebrovascular disease 203 (6.9) 69 (7.2) 101 (6.7) 33 (6.4) 0.82 83 (7.3) 31 (7.1) 27 (6.0) 25 (9.9) 0.16 0.59
Previous peripheral vascular arterial disease 276 (9.2) 114 (11.9) 115 (7.6) 47 (9.2) <0.01 95 (8.3) 39 (8.9) 33 (7.3) 23 (9.1) 0.59 0.36
Previous percutaneous coronary intervention 641 (21.4) 193 (20.1) 340 (22.4) 108 (21.1) 0.39 153 (13.4) 57 (13.1) 56 (12.4) 40 (15.8) 0.42 <0.001
Previous coronary artery bypass graft surgery 394 (13.2) 116 (12.1) 205 (13.5) 73 (14.2) 0.44 83 (7.3) 34 (7.8) 33 (7.3) 16 (6.3) 0.77 <0.01
Extent of coronary artery disease at baseline as assessed by coronary angiography, n (%)
No significant coronary artery disease 538 (18.0) 179 (17.7) 280 (18.5) 88 (17.2) 0.77 492 (43.1) 197 (45.2) 187 (41.3) 108 (42.7) 0.50 <0.001
1-vessel disease 704 (23.6) 218 (22.7) 373 (24.6) 113 (22.0) 0.38 254 (22.2) 88 (20.2) 109 (24.1) 57 (22.5) 0.38 0.37
2-vessel disease 731 (24.5) 236 (24.6) 360 (23.7) 135 (26.3) 0.50 192 (16.8) 72 (16.5) 80 (17.7) 40 (15.8) 0.80 <0.001
3-vesseldisease 1016 (34.0) 335 (34.9) 504 (33.2) 177 (34.5) 0.66 204 (17.9) 79 (18.1) 77 (17.0) 48 (19.0) 0.79 <0.001
Comorbidity at baseline, n (%)
Pulmonary disease 276 (9.2) 96 (10.0) 115 (7.6) 65 (12.7) 0.04 91 (8.0) 43 (9.9) 25 (5.5) 23 (9.1) <0.01 0.20
Cancer 4 (0.1) 2 (0.20) 1 (0.10) 1 (0.20) 0.59 0 (0.0) 0 0 0 - 0.22
Medication following baseline coronary angiography, n (%)
Acetylsalisylic acid 2546 (85.2) 810 (84.5) 1306 (86.1) 430 (83.8) 0.13 830 (72.7) 304 (69.7) 332 (73.3) 194 (76.7) 0.34 <0.001
Statins 2492 (83.4) 759 (79.1) 1296 (85.4) 437 (85.2) <0.001 818 (71.6) 305 (70.0) 330 (72.8) 183 (72.3) 0.61 <0.001
β-blockers 2229 (74.6) 684 (71.3) 1155 (76.1) 390 (76.0) 0.02 765 (67.0) 286 (65.6) 301 (66.4) 178 (70.4) 0.42 <0.001
ACE inhibitors 644 (21.5) 171 (17.8) 320 (21.1) 153 (29.8) <0.001 214 (18.7) 72 (16.2) 83 (18.3) 59 (23.3) 0.08 0.05
Loop diuretics 297 (9.9) 90 (9.4) 128 (8.4) 79 (15.4) <0.001 150 (13.1) 37 (8.5) 54 (11.9) 59 (23.3) <0.001 <0.01
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Table 2 Baseline characteristics and laboratory findings according to gender and BMI groupsa (Continued)
Coronary revascularization following baseline coronary angiography, n (%)
Percutaneous coronary intervention 1065 (35.6) 327 (34.1) 545 (35.9) 193 (37.6) 0.38 283 (24.8) 105 (24.1) 118 (26.0) 60 (23.7) 0.72 <0.001
Coronary artery bypass graft surgery 731 (24.5) 248 (25.9) 363 (23.9) 120 (23.4) 0.46 161 (14.1) 54 (12.4) 75 (16.6) 32 (12.6) 0.15 <0.001
Biochemical markers
Creatinine (μmol/L) 96.4 (31.7) 96.6 (30.5) 96.4 (34.9) 95.9 (23.3) 0.93 82.8 (26.5) 83.9 (36.7) 81.4 (14.5) 83.4 (21.5) 0.35 <0.001
eGFR (mL/min) 89.3 (17.0) 87.5 (16.6) 89.7 (16.6) 91.2 (16.9) <0.001 84.1 (17.3) 83.4 (17.6) 84.6 (16.1) 84.2 (18.7) 0.58 <0.001
CRP (mg/L) 3.66 (7.59) 3.55 (8.91) 3.58 (6.99) 4.07 (6.49) 0.39 3.79 (5.93) 2.88(5.17 3.62 (5.43) 5.66 (7.42) <0.001 0.59
Glucose (mmol/L) 6.41 (2.38) 6.08 (2.42) 6.33 (2.14) 7.26 (2.77) <0.001 6.20 (2.46) 5.60 (1.75) 6.30 (2.68) 7.06 (2.82) <0.001 0.01
HbA1c (mmol/L) 6.17 (1.39) 6.16 (1.11) 6.40 (1.52) 6.62 (1.49) <0.001 6.36 (1.38) 6.10 (1.36) 6.11 (1.37) 6.46 (1.43) <0.001 <0.001
Hemoglobin (g/dL) 14.6 (1.16) 14.2 (1.21) 14.7 (1.07) 14.8 (1.16) <0.001 13.4 (1.05) 13.3 (1.04) 13.5 (1.04) 13.5 (1.05) <0.01 <0.001
ApoA1 (g/L) 1.26 (0.25) 1.31 (0.27) 1.25 (0.23) 1.20 (0.23) <0.001 1.46 (0.27) 1.49 (0.28) 1.45 (0.26 1.42 (0.27) <0.01 <0.001
ApoB (g/L) 0.90 (0.25) 0.86 (0.24) 0.90 (0.24) 0.93 (0.27) <0.001 0.92 (0.25) 0.88 (0.24) 0.94 (0.26) 0.94 (0.25) <0.01 <0.01
Total cholesterol (mmol/L) 4.98 (1.17) 5.18 (1.12) 5.39 (1.14) 5.25 (1.16) 0.30 5.28 (1.14) 5.18 (1.12) 5.39 (1.14) 5.25 (1.16) 0.02 <0.001
LDL cholesterol (mmol/L) 3.05 (1.02) 3.03 (1.01) 3.06 (0.98) 3.07 (1.13) 0.64 3.19 (1.03) 3.08 (1.02) 3.30 (1.03) 3.18 (1.04) <0.01 <0.001
HDL cholesterol (mmol/L) 1.22 (0.33) 1.33 (0.38) 1.19 (0.29) 1.09 (0.26) <0.001 1.47 (0.42) 1.57 (0.44) 1.45 (0.39) 1.34 (0.37) <0.001 <0.001
Triglycerides (mmol/L) 1.85 (1.28) 1.48 (0.97) 1.91 (1.30) 2.32 (1.52) <0.001 1.62 (1.03) 1.34 (0.72) 1.67 (1.18) 2.00 (1.07) <0.001 <0.001
Lp(a) (mmol/L) 0.41 (0.37) 0.43 (0.41) 0.48 (0.45) 0.47 (0.40) 0.79 0.46 (0.42) 0.43 (0.41) 0.48 (0.45) 0.47 (0.40) 0.11 <0.01
WENBIT intervention trial, n (%) 2047 (68.5) 614 (64.0) 1072 (70.7) 361 (70.4) <0.01 513 (44.9) 183 (42.0) 211 (46.6) 119 (47.0) 0.29 <0.001
B6, n (% of WENBIT participants) 1043 (34.9) 320 (52.1) 553 (51.9) 170 (47.1) 0.19 239 (20.9) 89 (48.6) 96 (45.5) 54 (45.4) 0.94 <0.001
Folate/B12, n (% of WENBIT participants) 1031 (34.5) 301 (49.0) 555 (51.8) 175 (48.5) 0.03 244 (21.4) 93 (50.8) 102 (48.3) 49 (41.2) 0.92 <0.001
ACE, angiotensin converting enzyme; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, body mass index; CRP, c-reactive protein; eGFR, esitimated glomerular filtration rate; HDL, high density lipoprotein; LDL,
low density lipoprotein; Lp(a), lipoprotein (a).
aNormal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2).
bBased on differences between BMI groups among men, and was calculated by ANOVA for continuous variables and Chi squared test for categorical variables for differences between men and women.
cBased on differences between BMI groups among women, and was calculated by ANOVA for continuous variables and Chi squared test for categorical variables for differences between men and women.
dBased on between group differences in men vs. women, and was calculated by independent samples t-test for continuous variables and Chi squared test for categorical variables.
eMean (SD).
fIncludes DM type 1 and 2.
gSmokers included self-reported current smoking, those who quit smoking within <1 month and patients with plasma cotinine >85 ng/mL.
hPatients reported to have quit smoking > 1 month prior to inclusion.
iIncluded those reporting to have at least one 1st degree relative suffering from CAD before the age of 55 for men and 65 for women.
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Table 3 BMI groupsa and risk of acute myocardial infarction and cardiovascular death in men
Model Acute myocardial infarction Cardiovascular death
Events, n (%) HR 95% CI p-value Events, n (%) HR 95% CI p-value
Univariate
Normal weight 84 (8.8) 1.00 51 (5.3) 1.00
Overweight 117 (7.7) 0.88 0.66, 1.16 0.37 49 (3.2) 0.61 0.41, 0.90 0.01
Obese 66 (12.9) 1.51 1.09, 2.08 0.01 32 (6.2) 1.19 0.76, 1.85 0.45
Multivariate adjustedb
Normal weight 1.00 1.00
Overweight 1.11 0.84, 1.48 0.47 0.85 0.57, 1.28 0.44
Obese 1.80 1.28, 2.52 <0.01 1.60 1.00, 2.55 0.05
BMI, body mass index; CI, confidence interval; HR, hazard ratio.
aNormal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2).
bAge (continuous), current smoking (yes/no), left ventricular ejection fraction (%), pulmonary disease (yes/no), angiotensin converting enzyme-inhibitors (yes/no)
and loop diuretics (yes/no).
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http://www.biomedcentral.com/1471-2261/14/68of patients with CAD, have examined the association
between BMI and all-cause mortality in men and
women separately [7,8]. First, a study of Danish patients
with AMI showed that normal weight, overweight and
obese men had similar risk of death, whereas over-
weight women had a slightly decreased risk (HR (95%
CI); 0.78 (0.68, 0.90)) of death, as compared to their
normal weight counterparts. Furthermore, in a follow up
study of the CADILLAC trial, they observed significantly
lower in-hospital mortality (0.9% vs. 2.7%), 30 days (1.1%
vs. 3.8%) and 1- year (1.8% vs. 7.5%) mortality in obese
patients with AMI undergoing PCI when compared to
normal weight patients. Statistical significance was, how-
ever, only reached in males.Possible explanations
BMI is often used to quantify overweight and obesity
owing to a high fat percentage correlation, but does not
account for fat distribution. Men have a tendency toTable 4 BMI groupsa and risk of acute myocardial infarction a
Model Acute myocardial infarction
Events, n (%) HR 95% CI p-
Univariate
Normal weight 33 (7.6) 1.00
Overweight 21 (4.6) 0.61 0.35, 1.05
Obese 16 (6.3) 0.84 0.46, 1.53
Multivariate adjustedb
Normal weight 1.00
Overweight 0.56 0.33, 0.98
Obese 0.80 0.43, 1.47
BMI, body mass index; CI, confidence interval; HR, hazard ratio.
a Normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese
b Age (continuous), current smoking (yes/no), left ventricular ejection fraction (%), p
and loop diuretics (yes/no).store excessive fat in visceral fat deposits, whereas women
usually store fat in peripheral subcutaneous distributions
[4]. Excessive visceral fat is associated with an increased
risk of developing metabolic syndrome, putting men at a
greater risk of developing CVD, while subcutaneous fat in
the femoral-gluteal region may be associated with a more
favourable CV risk profile [22]. Furthermore, overweight
and obese postmenopausal women may benefit from the
increase in circulating levels of estrogen produced by the
adipose tissue [23,24].
Moreover, at baseline, men were more often affected
by CV risk factors and had more severe CAD. Inclusion
of these potential confounding variables in stratified
multivariate analyses did not alter our results. Differing
health status at baseline is thus unlikely to be the cause
of the observed gender interaction.
Strengths and limitations of the study
The main strength of the present study is its, well defined
population with complete follow up of clinical endpoints.nd cardiovascular death in women
Cardiovascular death
value Events, n (%) HR 95% CI p-value
16 (3.7) 1.00
0.08 13 (2.9) 0.78 0.38, 1.63 0.51
0.57 4 (1.6) 0.43 0.14, 1.28 0.13
1.00
0.04 0.71 0.34, 1.50 0.37
0.46 0.38 0.21, 1.16 0.09
(BMI ≥ 30 kg/m2).
ulmonary disease (yes/no), angiotensin converting enzyme-inhibitors (yes/no)
Borgeraas et al. BMC Cardiovascular Disorders 2014, 14:68 Page 9 of 10
http://www.biomedcentral.com/1471-2261/14/68Limitations include the single baseline measurements
of BMI and other time dependent cofactors such as
medication. We did not have sufficient data on possible
confounders such as physical activity, socioeconomic
status or cardio- respiratory fitness and intentional vs.
unintentional weight loss, and thus we cannot exclude
the possibility that residual confounding from unmeas-
ured causal factors unevenly distributed between BMI
groups may have influenced our results. Unfortunately,
we did not have data on recent weight loss prior to
inclusion, but as underweight patients (BMI <18.5 kg/m2)
were excluded, and adjustment for possible confounders
such as cancer, pulmonary disease, extent of significant
CAD and LVEF did not significantly alter our results,
reverse causation is unlikely. BMI was positively associ-
ated with common obesity related characteristics such
as higher blood pressure, diabetes, an unfavourable lipid
profile, higher eGFR and CRP. Adjustment for these vari-
ables did not have a significant effect on our results,
but we would in any case not include these variables in
a final multivariate adjusted survival model because of
the possibility of over-adjustment bias. We did, how-
ever, adjust for use of ACE inhibitors and loop diuretics
as a proxy of heart failure, and there is the possibility
that these variables may have mediated some of the
effect of BMI.
It has previously been suggested that BMI is an inad-
equate marker of overweight and obesity in patients with
CAD [25], with waist circumference or waist to hip ratio
suggested as better predictors of cardiovascular events,
especially in women [6,26]. Studies supporting an obesity
paradox have almost exclusively used BMI as an index of
obesity [3]. We thus suspect that the diverging findings
among such studies may be the result of BMI’s inadequacy
as a quantifier of true body fatness and fat distribution.
Given that there were relatively few females in the
study population and the event rate was low, we thus had
a low statistical power to by which to detect the possible
effects of BMI on risk of events among women. Further,
we cannot rule out that the relatively lower incidence rate
of AMI among women is a result of detection bias;
women, compared to men, are more likely to experience
atypical symptoms of AMI and may consequently delay
seeking medical care for symptoms or be misdiagnosed
by healthcare providers [27]. Finally, the inclusion of
predominantly white subjects limits the ability to gener-
alise our findings to non-white populations.
Conclusion
Among 4131 men and women with suspected stable an-
gina pectoris, obese men carried an 80% and 60% higher
risk of AMI and CV death, respectively, compared to
normal weight men, whereas being overweight, compared
to normal weight, was associated with a 50% lower riskof AMI among women. These findings may potentially
explain some of the result variation in studies reporting
on the obesity paradox, with further investigation of the
interaction between gender and BMI in terms of risk of
CV events and mortality therefore warranted.
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